5-Year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: A multicentre phase II study

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 3019-3024

  Barni, Sandro ^a   Visini, M ^b   Piazza, E ^c   Ionta, M T ^d   Ardizzoia, A ^e   Arnoldi, E ^f   Fava, S ^g   Pinotti, G ^h   Torretta, F ⁱ   Corradini, G ^j   Villa, S ^b   Nosenzo, A M ^c   Massidda, B ^d   Cazzaniga, M E ^a  

^a TREVIGLIO HOSPITAL   (Italy)

^b A MANZONI HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g Legnano Hospital   (Italy)

^h OSPEDALE DI CIRCOLO   (Italy)

ⁱ Tradate Hospital   (Italy)

^j RHO HOSPITAL   (Italy)

more..

Author keywords

Breast cancer; Cisplatin; Neoadjuvant

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR VOLUME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; VINBLASTINE;

EID: 34547806748     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bonadonna G, Zambetti M, Bumma C et al: Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group. Ann Oncol 13: 1049-1058, 2002.
2. Kuerer HM, Newman LA, Buzdar AU et al: Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy predicts axillary lymph node status. J Clin Oncol 17: 460-469, 1999.
3. Verril MW, Ashley SE, Walsh GA et al: Pathological complete response (pCR) in patients treated with neoadjuvant chemotherapy for operable breast cancer. Breast Cancer Res Treat Abs 549(50): 328, 1998.
4. Barni S, Ionta MT, Battelli T et al: L-PEV: a very challenging and active chemotherapy regimen in locally advanced breast cancer (LABC). Proc ASCO, Abs 331(32): 1999.
5. Miller AB, Hoogstraten B, Staquet M et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
6. Sataloff DM, Mason BA, Prestipino AJ et al: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180(3): 297-306, 1985.
7. Goldhirsch A, Wood WC, Senn HJ, Glick JH and Gelber RD: Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer 31A(11): 1754-1759, 1995.
8. Kaplan EL and Meyer P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
9. Barni S, Piazza E, Frontini L et al: Single agent epirubicin as primary chemotherapy in T2-3, N0-2, M0 breast carcinoma: 6-year follow up. Oncology 67(1): 40-47, 2004.
10. Ahlgren J, Lidbrink B, Lind L et al: Phase II study of epirubicin, cisplatin and capecitabine as neo-adjuvant chemotherapy in women with locally advanced or inflammatory breast cancer. Proc ASCO 27: Abs 107, 2003.
11. Frasci G, D'Aiuto G, Comella P et al: A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a Phase II study. Ann Oncol 16: 1268-1275, 2005.
12. Lee YJ, Doliny P, Gomez-Fernandez C et al: Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clin Breast Cancer 5(5): 371-376, 2004.
13. Ezzat AA, Ibrahim EM, Ajarim DS et al: Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 90(5): 968-974, 2004.
14. Smith IE, A'Hern RP, Coombes GA et al: A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 15(5): 751-758, 2004.